Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

l benefit response (CBR), time to progression (TTP), duration of response (DOR), progression-free survival, and best ORR throughout the study. Patients enrolled in the trial will receive carfilzomib twice weekly for three weeks every 28 days.

"Based on promising laboratory and clinical data, we believe that carfilzomib holds promise in treating patients with multiple myeloma, including those for whom other treatments have failed," said Sundar Jagannath, M.D., Saint Vincent's Comprehensive Cancer Center, where the first patient was enrolled. "We are excited to bring this compound into the MMRC as a critical step in bringing this new treatment to patients."

In the coming weeks, the MMRC and Proteolix will also begin enrolling an open-label, single-arm, Phase 2 study of carfilzomib in patients with relapsed multiple myeloma, who will be stratified by bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) history.

About Carfilzomib

Carfilzomib is a structurally- and mechanistically-novel proteasome inhibitor that exhibits a high level of selectivity for the unique N-terminal threonine active sites within the proteasome. Carfilzomib is similar to bortezomib in that it is a potent inhibitor of the proteasome chymotrypsin- like activity, but unlike bortezomib, carfilzomib has shown minimal cross- reactivity with the other catalytic sites within the proteasome or across other protease classes. Phase 1 clinical studies confirmed that patients who have relapsed or progressed following multiple therapies can still achieve durable anti-tumor responses with carfilzomib. In addition to the two Phase 2 single-agent trials in myeloma and ongoing studies in lymphoma, a clinical trial in solid tumors and a trial exploring carfilzomib in combination with an FDA-approved agent will be initiated by the end of the year.

"The Phase 1 data consistently demonstrate carfilzomib anti-tumor activity in myeloma patients who have failed multiple lines of therapy,
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Spain , March 3, 2015  AT&T 1 ... PHIA) today announced that  AT&T  is the connectivity provider ... GoSafe was designed to help provide peace of mind ... them the freedom to live active lives with the ... they need it. The AT&T network 2 helps ...
(Date:3/3/2015)... , March 3, 2015 Today, the ... sponsored by America,s biopharmaceutical research companies, unveiled a ... functionality to provide patients and caregivers with faster, ... public and private patient assistance programs. ... provided a platform to engage, educate and empower ...
(Date:3/3/2015)... - CPhI and P-MEC China ... Shanghai, China - The ... be held at Shanghai New International Expo Center, on 24th ... CPhI Worldwide and was introduced to China in 2001. It ... pharmaceutical companies and global pharmaceutical industry over the past 15 ...
Breaking Medicine Technology:AT&T Providing Connectivity for Philips GoSafe Mobile Medical Alert System, Empowering United States Seniors to be Connected to Emergency Care On-the-Go 2AT&T Providing Connectivity for Philips GoSafe Mobile Medical Alert System, Empowering United States Seniors to be Connected to Emergency Care On-the-Go 3AT&T Providing Connectivity for Philips GoSafe Mobile Medical Alert System, Empowering United States Seniors to be Connected to Emergency Care On-the-Go 4Partnership for Prescription Assistance Relaunches Website with New Features for Patients and Caregivers 215th Anniversary, Be Part of Chinese Pharma Dream 215th Anniversary, Be Part of Chinese Pharma Dream 3
(Date:3/3/2015)... York, NY (PRWEB) March 03, 2015 Daylight ... this spring. Sanjeev Kothare, MD, has tips for parents. , ... come March 8 at 2:00 a.m. when they set their ... when you wake up that day -- one hour earlier ... , That’s why parents should start thinking about “sleep hygiene” ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Sunday, March 1, ... No matter the time of year, every region of the ... , That’s why Amica Insurance is sharing the ... and Ready.gov to help keep you safe in the event ... Keep dry: Change wet clothing frequently to prevent loss of ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 -- vRad ( Virtual Radiologic ... today announced that Arlene Sussman, MD, a highly regarded ... live webinar to explore how telemedicine best practices allow ... services for women virtually anywhere. Click here ... Line” on March 4, 2015 at 1:00 pm CT. ...
(Date:3/3/2015)... 03, 2015 Splashtop Inc. , ... Mirroring360 is now available for Epson® MoverioTM BT-200 smart ... Moverio Apps Market , iPod, iPhone, and iPad ... to the Epson Moverio smart glasses using Mirroring360, enhancing ... , The Epson smart glasses have an advanced ...
(Date:3/3/2015)... March 03, 2015 According to ... http://www.idataresearch.com ), market saturation has made neurosurgery navigation ... the United States. Unit sales growth moderately increased ... as facilities replace older systems, and as new ... market is very much a replacement and upgrade ...
Breaking Medicine News(10 mins):Health News:Don’t Let Daylight Savings Disrupt Your Child’s Sleep 2Health News:Amica Insurance Has Tips for National Severe Weather Preparedness Week 2Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 2Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 3Health News:Latest vRad Webinar: Building World-Class Breast Imaging Services Virtually Anywhere with Telemedicine Best Practices 4Health News:Splashtop’s Mirroring360 Now Available for Epson® MoverioTM BT-200 Smart Glasses, Enabling Viewing of iOS Apps and Content on Glasses 2Health News:Splashtop’s Mirroring360 Now Available for Epson® MoverioTM BT-200 Smart Glasses, Enabling Viewing of iOS Apps and Content on Glasses 3Health News:Neurosurgery Navigation System Market Reaches Saturation in the United States 2Health News:Neurosurgery Navigation System Market Reaches Saturation in the United States 3
... ... by the U.S. Food and Drug Administration (FDA), Immunovative Therapies, Ltd. ... vaccine product for the treatment of advanced metastatic solid tumors will begin ... inside the body by combining the experimental AlloStimTM drug with the killing ...
... ... software for long-term care will present a technology and admissions educational session for THCA ... Atlanta, ... Web-based admissions for long-term care providers, announced today that it will present a session ...
... ... ,fight the bite, from America,s most unwanted species; the aggressive, disease-carrying, Asian Tiger mosquito ... Mega-Catch™ mosquito traps. , ... Auckland, NZ (PRWEB) August 14, 2009 -- The patent-pending, Mega-Catch™ 3000 combo lure ...
... ... 40% of women find holidays more stressful than they should be. A male,s ... is their biggest nightmare. Under 30s are the most stressed on holiday. , ... Cardiff, UK (PRWEB) August 14, 2009 ...
... , , , SACRAMENTO, ... contribution of up to $81.4 million to the Healthy Families Program today ... at risk of losing coverage due to the state,s fiscal crisis. The ... used to cover children ages 0-5 through June 2010. , , ...
... find types of hormones used raise or lower clot ... composition of a woman,s contraceptive pill influences her risk ... European researchers say. , Scientists have long known that ... progestogen, increase the likelihood of deep vein thrombosis of ...
Cached Medicine News:Health News:CryoStim™ Cancer Treatment to Begin FDA Clinical Trials September 1, 2009 2Health News:CryoStim™ Cancer Treatment to Begin FDA Clinical Trials September 1, 2009 3Health News:Patient Placement Systems Presents a Session at the THCA 2009 Annual Convention 2Health News:Patient Placement Systems Presents a Session at the THCA 2009 Annual Convention 3Health News:Mega-Catch™ 3000 Combination Lure Attracts Asian Tiger Mosquitoes (Aedes Albopictus) 2Health News:Mega-Catch™ 3000 Combination Lure Attracts Asian Tiger Mosquitoes (Aedes Albopictus) 3Health News:Spain Has The 'Stress' Factor, According to Confused.com 2Health News:Spain Has The 'Stress' Factor, According to Confused.com 3Health News:First 5 California Approves $81.4 Million Contribution to Help Restore Healthy Families Program's Viability 2Health News:Some Birth Control Pills Safer Than Others 2Health News:Some Birth Control Pills Safer Than Others 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: